The numbers tell a stark story of transformation. BioNTech’s revenue has collapsed from €17.3 billion in 2022 to roughly €2.87 billion last year, as its Covid vaccine franchise fades. Yet the company sits on a war chest of €16.8 billion in cash and securities — a cushion that buys time, but not patience.
When the Mainz-based biotech reports second-quarter earnings on August 4, the market will be looking past the income statement entirely. The real question is whether the oncology pipeline can deliver before that cash pile starts to feel like a liability.
A Stock in Limbo
Shares closed Friday at €78.75, down 2.66 percent on the day and roughly 25.6 percent below the 52-week high of €105.80 hit in January. The stock is hovering just under its 50-day moving average of €79.39 — a technical level that has become a psychological battleground.
The relative strength index sits at 43.2, signaling neither momentum nor exhaustion. After twelve months of 19.15 percent losses, the market appears to be waiting for concrete evidence before taking a side. The 52-week low of €68.35, untouched since March, marks the floor should sentiment sour further.
The Pipeline Puzzle
BioNTech has radically reshaped its portfolio, with more than 25 programs in Phase 2 and Phase 3 trials targeting oncology. The company aims to launch a “first wave” of new cancer therapies by 2030. Central to that ambition is Pumitamig (BNT327), a bispecific antibody widely viewed as the most important candidate in the pipeline.
Encouraging data from the ASCO 2026 congress showed both Pumitamig and the antibody-drug conjugate Gotistobart demonstrating credible anti-tumor activity. But the company recently trimmed its expectations: BioNTech now forecasts six late-stage readouts for 2026, down from the originally promised seven. In the high-stakes world of oncology trials, even a single delay can trigger a re-rating.
Should investors sell immediately? Or is it worth buying BioNTech?
Bulls vs. Bears
Optimists point to the balance sheet first. The €16.8 billion reserve allows BioNTech to sustain its R&D spending despite a first-quarter operating loss of €531.9 million. The average analyst price target stands at €107.37, implying roughly 36 percent upside from current levels — a bet that the market is underpricing the oncology strategy.
Skeptics see a company deep in the red, with a stock that has shed more than a quarter of its value since January. They note that each delay in a pivotal study risks further erosion of credibility. The technical picture offers no clear direction, and the market appears to be waiting for regulatory milestones before committing capital.
The Legal Wildcard
Adding to the uncertainty is a patent dispute that could resurface during the earnings call. Arbutus Biopharma and Genevant Sciences are challenging BioNTech’s lipid nanoparticle technology, which underpins both the Covid vaccine and the entire mRNA platform. An unfavorable outcome would have implications far beyond a single product line.
BioNTech rarely goes it alone in oncology. Partners including Bristol Myers Squibb, Genentech, Genmab, and Pfizer share much of the development risk. But the patent threat strikes at the core technology, making it a risk that partnership structures cannot easily mitigate.
What to Watch on August 4
The earnings report will provide the next hard catalyst. If management confirms the 2026 clinical timeline and signals strong patient enrollment across the 13 ongoing registration trials, the path toward the €107.37 target remains open. If the company reports further pipeline delays or higher-than-expected cash burn, the 52-week low could come into play by late summer.
For now, the stock drifts in a narrow range, caught between a fading legacy business and a future that has not yet arrived. The August 4 update will determine which direction the next chapter takes.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 26 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 26.
BioNTech: Buy or sell? Read more here...
